Review

. 2024 Jun;130(12):2027-2036.

doi: 10.1038/s41416-024-02733-4. Epub 2024 Jun 4.

Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice

Olga Tsoulaki^{1

2}, Marc Tischkowitz³, Antonis C Antoniou⁴, Hannah Musgrave⁵, Gillian Rea⁶, Ashu Gandhi⁷, Karina Cox⁸, Tracey Irvine⁹, Sue Holcombe¹⁰, Diana Eccles¹¹, Clare Turnbull¹², Ramsey Cutress¹³; Meeting Attendees; Stephanie Archer^#^{4

14}, Helen Hanson^#^{15

16

17}

Collaborators, Affiliations

Collaborators

Meeting Attendees:
Avgi Andreou, Abdul Badran, Marion Bartlett, Cheryl Berlin, Kathie Binysh, Paul Brennan, Ruth Cleaver, Gemma Corbett, Rosemarie Davidson, Bianca DeSouza, Rachel Evers, Lorenzo Ficorella, Suzannah Fitzgerald, Andrea Forman, Fiona Gilbert, Rochelle Gold, Steph Greville-Heygate, Sarah Hamilton, Carrie Hammond, Rachel Hart, Lara Hawkes, Jude Hayward, Debbie Holliday, Antony Howell, Gillian Hutchison, Jacqui Jenkins, Rosalyn Jewell, Grace Kavanaugh, Zoe Kemp, Victoria Kiesel, Ajith Kumar, Fiona Lalloo, Zosia Miedzybrodzka, Jennie Murray, Sian Nisbet, Della Ogunleye, Anbalakan Paramasivam, Claire Searle, Adam Shaw, Eamon Sheridan, Lucy Side, Katherine Smith, Beverley Speight, William Teh, Eleanor Thorpe, Anna Whaite, Louise Wilkinson, Siobhan Wilkinson, Emma R Woodward, Alice Youngs

Affiliations

¹ St George's University of London, London, UK.
² Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, UK.
³ Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.
⁴ Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
⁵ Yorkshire Regional Genetics Service, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
⁶ Northern Ireland Regional Genetics Service, Belfast City Hospital, Belfast, UK.
⁷ Manchester University Hospitals; Manchester Breast Centre, Division of Cancer Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK.
⁸ Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK.
⁹ Royal Surrey NHS Foundation Trust, Guildford, UK.
¹⁰ Association of Breast Surgery, London, UK.
¹¹ Department of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
¹² Translational Genetics Team, Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
¹³ University of Southampton and University Hospital Southampton, Somers Research Building, Tremona Road, Southampton, UK.
¹⁴ Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
¹⁵ Translational Genetics Team, Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK. H.Hanson@exeter.ac.uk.
¹⁶ Department of Clinical Genetics, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK. H.Hanson@exeter.ac.uk.
¹⁷ Faculty of Health and Life Sciences, University of Exeter Medical School, Exeter, UK. H.Hanson@exeter.ac.uk.

^# Contributed equally.

PMID: 38834743
PMCID: PMC11183136
DOI: 10.1038/s41416-024-02733-4

Review

Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice

Olga Tsoulaki et al. Br J Cancer. 2024 Jun.

. 2024 Jun;130(12):2027-2036.

doi: 10.1038/s41416-024-02733-4. Epub 2024 Jun 4.

Authors

Collaborators

Meeting Attendees:
Avgi Andreou, Abdul Badran, Marion Bartlett, Cheryl Berlin, Kathie Binysh, Paul Brennan, Ruth Cleaver, Gemma Corbett, Rosemarie Davidson, Bianca DeSouza, Rachel Evers, Lorenzo Ficorella, Suzannah Fitzgerald, Andrea Forman, Fiona Gilbert, Rochelle Gold, Steph Greville-Heygate, Sarah Hamilton, Carrie Hammond, Rachel Hart, Lara Hawkes, Jude Hayward, Debbie Holliday, Antony Howell, Gillian Hutchison, Jacqui Jenkins, Rosalyn Jewell, Grace Kavanaugh, Zoe Kemp, Victoria Kiesel, Ajith Kumar, Fiona Lalloo, Zosia Miedzybrodzka, Jennie Murray, Sian Nisbet, Della Ogunleye, Anbalakan Paramasivam, Claire Searle, Adam Shaw, Eamon Sheridan, Lucy Side, Katherine Smith, Beverley Speight, William Teh, Eleanor Thorpe, Anna Whaite, Louise Wilkinson, Siobhan Wilkinson, Emma R Woodward, Alice Youngs

Affiliations

¹ St George's University of London, London, UK.
² Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust, Manchester, UK.
³ Department of Medical Genetics, National Institute for Health Research Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.
⁴ Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
⁵ Yorkshire Regional Genetics Service, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
⁶ Northern Ireland Regional Genetics Service, Belfast City Hospital, Belfast, UK.
⁷ Manchester University Hospitals; Manchester Breast Centre, Division of Cancer Sciences, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, UK.
⁸ Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK.
⁹ Royal Surrey NHS Foundation Trust, Guildford, UK.
¹⁰ Association of Breast Surgery, London, UK.
¹¹ Department of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
¹² Translational Genetics Team, Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK.
¹³ University of Southampton and University Hospital Southampton, Somers Research Building, Tremona Road, Southampton, UK.
¹⁴ Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
¹⁵ Translational Genetics Team, Division of Genetics and Epidemiology, Institute of Cancer Research, London, UK. H.Hanson@exeter.ac.uk.
¹⁶ Department of Clinical Genetics, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK. H.Hanson@exeter.ac.uk.
¹⁷ Faculty of Health and Life Sciences, University of Exeter Medical School, Exeter, UK. H.Hanson@exeter.ac.uk.

^# Contributed equally.

PMID: 38834743
PMCID: PMC11183136
DOI: 10.1038/s41416-024-02733-4

Abstract

Background: The CanRisk tool, which operationalises the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) is used by Clinical Geneticists, Genetic Counsellors, Breast Oncologists, Surgeons and Family History Nurses for breast cancer risk assessments both nationally and internationally. There are currently no guidelines with respect to the day-to-day clinical application of CanRisk and differing inputs to the model can result in different recommendations for practice.

Methods: To address this gap, the UK Cancer Genetics Group in collaboration with the Association of Breast Surgery and the CanGene-CanVar programme held a workshop on 16^th of May 2023, with the aim of establishing best practice guidelines.

Results: Using a pre-workshop survey followed by structured discussion and in-meeting polling, we achieved consensus for UK best practice in use of CanRisk in making recommendations for breast cancer surveillance, eligibility for genetic testing and the input of available information to undertake an individualised risk assessment.

Conclusions: Whilst consensus recommendations were achieved, the meeting highlighted some of the barriers limiting the use of CanRisk in clinical practice and identified areas that require further work and collaboration with relevant national bodies and policy makers to incorporate wider use of CanRisk into routine breast cancer risk assessments.

PubMed Disclaimer

Conflict of interest statement

RC received institutional research funding from SECA and Astra-Zeneca. ACA is listed as creator of the BOADICEA model that was licensed by Cambridge Enterprise (University of Cambridge). All other authors declare no conflict of interest.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49. doi: 10.3322/caac.21660. - DOI - PubMed
1. Cancer Research UK. Breast cancer statistics. https://www.cancerresearchuk.org/health-professional/cancer-statistics/s.... Accessed 20 Nov 2023.
1. Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M The benefits and harms of breast cancer screening: an independent reviewThe Independent UK Panel on Breast Cancer Screening. 2013 [cited 2023 Nov 20]; Available from: www.bjcancer.com.
1. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer Clinical guideline. 2013 [cited 2023 Nov 20]; Available from: www.nice.org.uk/guidance/cg164.
1. Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S, et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med. 2019;21:1708–18. doi: 10.1038/s41436-018-0406-9. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice

Collaborators

Affiliations

Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice

Authors

Collaborators

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous